The Procter Gamble Company

Andrew John Tofe

Marion David Francis

Frederick Anthony Hartman

Herbert C Kretschmar

A composition and method for the preparation of a technetium-99 m based scintigraphic scanning agent are disclosed. The agent is prepared by the addition of a pertechnetate-99 m solution to an anhydrous salt composition comprising a phosphonic acid or a pharmaceutically acceptable salt thereof and a non-toxic, water-soluble, anhydrous, stannous, ferrous or chromous salt of hydrochloric or sulfuric acid.

Radiographic scanning

Physiologically acceptable particulate radionuclide carriers comprising a reducing agent bound to an anionic starch derivative, useful in the preparation of organ-specific diagnostic radiopharmaceuticals.

Radionuclide carriers

A composition and method for the preparation of a technetium-99m based scintigraphic scanning agent are disclosed. The agent is prepared by the addition of a pertechnetate-99m solution to an anhydrous salt composition comprising a phosphonic acid or a pharmaceutically acceptable salt thereof and a non-toxic, water-soluble, anhydrous, stannous, ferrous or chromous salt of hydrochloric or sulfuric acid.

Dry mixture containing diphosphonates and a stannous salt useful in the

Composition in unit dosage form comprising mono-, di- and polyphosphonate compounds having therapeutic levels of radioactive phosphorus (as .sup.32 P and .sup.33 P) incorporated therein are disclosed. Due to the extremely high affinity of the polyphosphonate compounds for active bone tumors and their exceptionally low retention in soft tissue they are ideal for therapy of both primary and metastatic bone tumors and soft tissue tumors which calcify.

Growing community of inventors

Cincinnati, OH, United States of America

Andrew John Tofe